Aim: Cirrhosis places a substantial burden on the psychological status of affected individuals. The aim of our study was to identify the associated factors of psychological distress in cirrhosis.
INTRODUCTION

L
IVER CIRRHOSIS, THE end stage of a variety of chronic hepatic diseases, can lead to a progressive loss of liver function and has a poor prognosis. It is a major health problem associated with significant morbidity and mortality worldwide, especially in Asian countries, where the prevalence of chronic hepatitis B and C is high. 1 As there is no ideal cure for cirrhosis, current treatment strategies are mainly aimed at relieving disturbing symptoms, slowing down the progression of the disease, and improving the quality of life.
Growing evidence has indicated that liver cirrhosis carries a significant burden on the psychological status of affected individuals. The majority of cirrhotic patients show mild to moderate, even severe, depression and anxiety and the health-related quality of life of patients is remarkably reduced by psychological distress rather than liver impairment. [2] [3] [4] However, limited studies have investigated the factors that influence the psychological status of cirrhotic patients. The severity of cirrhosis as assessed by the CP score does not seem to be related to depression or anxiety. 5 Increased aspartate transaminase has been identified as a physiologic factor associated with psychological distress in cirrhosis. 5 Gastrointestinal symptoms occur frequently in cirrhotic patients. Many investigations have confirmed that GI symptoms are strongly associated with the psychological distress in patients with GI disorders as well as in patients with diabetes mellitus. [6] [7] [8] Only very few studies have shown the association between GI symptomatology and psychological dysfunction in cirrhosis. 9, 10 Brain-derived neurotrophic factor belongs to the neurotrophin family of growth factors, playing an essential role in the survival, differentiation, and outgrowth of peripheral and central neurons. 11 Extensive investigations have indicated that decreased serum BDNF concentration is associated with depression and antidepressant treatment can restore the decreased BDNF level to the normal value. [12] [13] [14] Published data also showed that the development of depressive symptoms during interferon-α therapy in hepatitis C patients was significantly associated with decrease in serum BDNF level. 15 No data exist to date on the relationship between depression status and BDNF level in cirrhosis.
The aim of the current study was to identify the associated factors of psychological distress in cirrhosis. We investigated the relationships between demographic variables (including age, gender, education, income, etiology, and duration of cirrhosis), disease severity, GI symptoms, and serum BDNF level with the presence of depression and anxiety in a group of cirrhotic patients.
METHODS
Patients
B
ETWEEN JULY 2011 and December 2012 consecutive patients with cirrhosis during hospital admission at the Liver Cirrhosis Section, Department of Hepatology in Shuguang Hospital (Shanghai, China) were enrolled in the study. The criterion for inclusion was a diagnosis of cirrhosis based on liver biopsy or a combination of radiological, endoscopic, and biochemical findings. Exclusion criteria were: (i) a history of major mental diseases such as major depression, schizophrenia, or bipolar disorder; (ii) current use of psychiatric medications; (iii) suspected HCC; (iv) active GI bleeding; and (v) inability to complete questionnaires owing to severe cirrhosis complications or comorbid illness. Patients with viral hepatitis were not actively treated with interferon either at the time of investigation or during the previous 12 months. Additionally, 60 healthy controls recruited from routine medical examinations during the same period were also included in the present study. Control subjects had no clinical and psychiatric comorbidities or family history of psychiatric disease.
Two physicians were trained to record demographic and clinical data, check completeness of data, and carry out questionnaire collections. Demographic and clinical details included age, gender, education, income, duration of illness, history of viral hepatitis, alcohol dependence, current therapy, routine biochemistry, and five items of the CP score (serum albumin and bilirubin levels, prothrombin activity, presence and severity of ascites, and encephalopathy).
The study protocol was in accordance with the guidelines for clinical research and was approved by the Institutional Review Board and the Ethical Review Committee of the hospital.
Assessment of GI symptoms
We evaluated the frequency and severity of GI symptoms experienced over the previous 12 months. Six different GI symptoms were extracted from the Gastrointestinal Symptom Rating Scale. 16 In addition, "anorexia" was added to the list on the questionnaire as it was a common complaint in our patients. Each symptom was rated on a 4-point scale: 0, not present; 1, mild; 2, moderate; and 3, severe. A higher score indicated higher severity of GI dysfunction. The questionnaire was self-administered with the help of two physicians who were unaware of the evaluations of the psychological status of the patients.
Psychological measurements
The 24-item HAMD was used to assess the severity of depressive symptoms in each participant. 17 The HAMD is a commonly used clinician-rated depression symptom rating scale and has been found to have high reliability and validity in Chinese populations. The HAMD index, equal to or above 20, suggests the presence of depression. Anxiety was evaluated with the HAMA, 18 which consists of 14 items, graded from 0 (not present) to 4 (maximally present). Higher scores indicate higher severity of anxiety. Scores equal to or above 14 are indicative of clinically significant levels of anxiety; scores below 14 are considered as no significant psychopathology. The evaluations were carried out by two qualified raters who were blind to the demographic and clinical details of the patients.
Determination of serum BDNF levels
Serum BDNF levels were measured using enzyme-linked immunosorbent assay kits (Quantikine Human BDNF; R&D Systems, Wiesbaden, Germany) after appropriate dilution of samples according to the manufacturer's instructions. Each assay was carried out in duplicate. The BDNF standard provided with this system was used to generate a standard curve that was linear between 0.75 and 12 μg/L. Minimum detectable concentration is 0.5 μg/L. The absorbance at 450 nm was measured with a microplate reader and BDNF concentrations were determined automatically according to the standard curve.
Statistical analysis
Data are expressed as mean ± standard deviation or median values (interquartile range) as appropriate. SPSS version 15.0 (SPSS, Chicago, IL, USA) software was used for the statistical analysis. Student's t-test or the MannWhitney U-test was applied as appropriate in order to compare continuous variables. The χ 2 -test was used for comparison of categorical variables. To identify independent predictors of depression or anxiety, all parameters univariately correlated at P < 0.1 with HAMD or HAMA scores were entered into stepwise linear multiple regression analysis. All reported P-values are two-tailed and P < 0.05 was considered as the cut-off value for significance.
RESULTS
T
WO HUNDRED AND eight patients with confirmed liver cirrhosis (127 males, 81 females, aged 26-86 years) met the criteria and were included in the present study. The etiology was virus-related (hepatitis B and/or hepatitis C) in 139 patients, alcoholic in 15 patients, and cholestatic in 11 patients. Five patients had a disease of autoimmune origin and 38 patients had another (schistosomal, metabolic, etc.) or a mixed etiology. There were no active drinkers at the time of the investigation. Of 208 patients, 74 were classified as CP class A, 91 were class B, and 43 were class C. Eighty-two patients had developed ascites.
Of all participants, 16.35% (n = 34) were classified as being cases of depression and 10.58% (n = 22) were diagnosed with anxiety. The symptoms of depression and anxiety were found to co-exist in 19 patients. Our results suggested that there were no significant differences in mean age, duration of illness, etiology, CP score, ascites, education, or household income between the patients who suffered from depression and those who did not. However, the percentage of female patients in the group classified as depressed was significantly higher than that in the non-depressed group (58.8% vs. 35.1%, P = 0.009). Similarly, no clinical or demographical differences were observed between patients with and without anxiety, except for female gender (77.3% vs. 34.4%, P < 0.001) (see Table 1 ).
The GI symptoms in our cirrhotic population in order of decreasing prevalence were: abdominal bloating (prevalence 40.38%), belching (36.06%), anorexia (34.13%), abdominal pain (31.73%), nausea/vomiting (15.87%), loose/watery stools (15.38%), and constipation (12.50%) (Fig. 1a) . Of 208 patients, 77.88% were confirmed to experience one or more troublesome GI symptom, two or more GI symptoms were reported by 50.96%, three or more by 33.65%, and four or more by 17.79%.
As illustrated in Figure 1 (b,c), the Hamilton depression scores of patients with three or more GI symptoms were 13(8, 21.25), which were significantly higher than that of patients with one or two GI symptoms (13 [8, 21.25] vs. 8 [5, 12] , P < 0.001) and that of patients without GI symptoms (13 [8, 21.25 ] vs. 5 [2.75, 10], P < 0.001). There was also significant difference in HAMD scores between the patients with one or two GI symptoms and those without GI symptoms (8 [5, 12] vs. 5 [2.75, 10], P = 0.00233). Similarly, the patients with three or more GI symptoms showed significantly higher anxiety scores than those with one or two GI symptoms (8 [4, 12] vs. 4 [2, 8] , P < 0.001) or those free of GI symptoms (8 [4, 12] vs. 3 [2, 5] , P < 0.001).
As shown in Figure 1 (d,e), the GI symptom scores of patients with depression were significantly higher than that of patients without depression (4 [2.75, 7] vs. 2 [0, 4], P < 0.001). Similarly, the patients with anxiety had significantly higher GI symptom scores than those free of anxious symptoms (4 [2.75, 7.25] vs. 2 [1, 4] , P < 0.001).
The HAMD and HAMA scores in patients with GI symptoms were compared with those who were free of GI symptoms for each individual symptom (see Table 2 ). Significantly higher depression scores were detected in patients who suffered from abdominal bloating (11 [6.25, 15 .75] vs. 7.5 [4, 12. 75], P = 0.002), belching (10 [6, 18] vs. 8 [4, 13] , P = 0.011), anorexia (13 [8, 20] vs. 7 [4, 11] , P < 0.001), abdominal pain (12 [6.75, 20] vs. 8 [4, 12] , P < 0.001), nausea/vomiting (16 [10.5, 30] vs. 8 [4, 13] , P < 0.001), and constipation (13 [8.5, 19 .75] vs. 8 [4, 14] , P = 0.004). Similarly, anxiety scores were significantly higher in patients with abdominal bloating (7 [3, 9] vs. 4 [2, 7] , P = 0.003), belching (7 [3, 10] vs. 4 [2, 8] , P = 0.008), anorexia (7 [4, 11] vs. 4 [2, 7] , P < 0.001), abdominal pain (7 [3.75, 12.25] Patients who were classified as being cases of depression showed significantly more frequent symptoms of anorexia (55.88% vs. 29.88%, P = 0.003), abdominal pain (58.82% vs. 26.43%, P < 0.001), and nausea/vomiting (44.12% vs. 10.34%, P < 0.001) than non-depressed patients. In patients with anxiety, abdominal pain (68.18% vs. 27.42%, P < 0.001), nausea/vomiting (59.09% vs. 10.75%, P < 0.001), and constipation (27.30% vs. 10.75%, P = 0.027) were significantly more frequent ( Multiple linear regression analysis was used to identify the possible covariates related to depression and anxiety. Female gender, CP scores, the number of GI symptoms, GI symptom scores, and BDNF level were included in the analysis as possible covariates. Our results showed that female gender and GI symptom scores were independently associated with HAMD and HAMA scores (see Table 4 ). The serum level of BDNF was not related to either depression or anxiety.
DISCUSSION
T HE PRESENT STUDY has indicated a significant association between GI symptoms and psychological distress in liver cirrhosis. Being female also creates a higher risk of suffering depression and anxiety in cirrhotic patients. Moreover, our data have reported for the first time that there is no significant correlation between the serum concentration of BDNF, which has been considered as a potential biomarker of depression, and psychological distress in cirrhosis. Data are presented as mean ± standard deviation, median (interquartile range), or n (%) as appropriate.
Risk factors of depression and anxiety in cirrhosis E67
Patients with cirrhosis are living with substantial psychological and social challenges. Available data reported that a remarkable proportion of cirrhotic patients (57%) were detected with depression, 27% with state-anxiety and 28% with trait-anxiety. 4 A study involving 156 Italian patients with cirrhosis revealed that 56.7% of patients had global BDI scores suggestive of depression and 10% had moderate to severe depression. 3 The HAMD, as an observer-rated scale, and the BDI, as a self-rated scale, are the most commonly used instruments for measuring the severity of depressive symptoms. The data of available investigations have shown a satisfactory concordance between HAMD and BDI. 19 A meta-analysis including 19 trials suggested that HAMD was more sensitive and thus potentially overreactive as the raters were aware of the clinical data and treatment. 20 In the present study, the raters were totally blind to the demographic and clinical details of the patients to exclude a possible bias. A HAMD cutoff score ≥ 20 was considered as indicative of clinically significant level of depression and a HAMA score ≥ 14 as indicative of significant anxiety. 17, 18 Therefore, the patients with mild depression or anxiety, in other words, those who "might have depression or anxiety", were excluded during the psychological evaluation in our study. In our sample, 16.35% of cirrhotic patients were suffering from significant depressive symptoms and 10.58% had significant anxiety. The results were consistent with the data of the previous studies, although there were differences existing in sample size and in psychological measurements.
Psychological distress can be a contributory factor to deteriorating medical condition, therefore psychological assessment and identification of the associated factors of psychological distress are of considerable importance. Previous studies reported that gender, etiology, and duration of disease did not show significant relationships with health-related quality of life in cirrhotic patients. 21, 22 In a study including 80 patients with chronic liver diseases (compensated cirrhosis or chronic hepatitis), the degree of psychological distress was not related to gender, age, treatment, duration of disease, or hepatic histological changes. 23 Increased serum aspartate transaminase and abnormal autonomic nervous activities by heart rate variability analysis were associated with psychological disturbance in cirrhosis. 5 It is still controversial whether psychological profiles correlate with CP scores. 24 Our results indicated that female cirrhotic patients showed a higher risk of suffering depression and anxiety, whereas other factors including age, etiology, illness duration, education status, salary, ascites, and CP score did not show a significant relationship with depression and anxiety scores. In fact, mounting evidence has confirmed the gender difference in psychological distress. The lifetime prevalence of major depressive disorder and any anxiety disorder in women is Data are presented as median (interquartile range). 1.5 times that of men. 25, 26 However, the gender differences in psychological function are strongly affected by advanced old age, which may remove the influence of gender roles. 27 Thus we consider that the female predominance in psychological distress may be influenced by the age composition of the population. There are many published reports on the important role of GI symptoms in the psychological profile of patients with GI disorders as well as non-GI disorders, such as diabetes mellitus. However, investigations of a potential association between psychological distress and GI symptoms in cirrhosis have been extremely limited. 9, 10 Gastrointestinal symptoms are frequently observed in patients with liver cirrhosis due to the structural changes in the GI tract (e.g., esophageal varices and portal hypertensive gastropathy), abnormalities in the sensorimotor and barrier function of the gut, and small bowel bacterial overgrowth. 28 In cirrhotic patients, gastric emptying and small bowel transit are significantly delayed compared to healthy controls. In patients with cirrhosis and portal hypertension, gastroesophageal reflux occurs at a high frequency (64%). 29 A study including 78 cirrhotic patients 30 In the present study, 77.88% of cirrhotic patients experienced one or more disturbing GI symptoms, with bloating being the most frequent symptom (prevalence rate, 40.38%). The prevalence rate recorded in our study is similar to that reported by Fritz and Hammer. 9 However, there were remarkable differences in the type and prevalence of GI symptoms between their study and ours. In our cirrhotic patient group, patients barely complained of dysphagia, heartburn, anal pain, fecal incontinence, or symptomatic piles, but instead suffered from belching, abdominal pain, nausea/vomiting, and poor appetite more frequently. These different results may depend on the differences in cirrhotic population samples. Our data also indicated that depression and anxiety scores in cirrhotic patients were significantly associated with specific GI symptoms (abdominal bloating/pain, belching, nausea/vomiting, anorexia, and constipation) and were positively correlated with GI symptom scores. The prevalence of nausea/vomiting and abdominal pain was significantly higher in depressive and anxious patients. Therefore, to relieve troublesome GI symptoms is of considerable importance for cirrhotic patients.
Brain-derived neurotrophic factor has been considered a valid indicator of a depressive state. It is mainly produced in the brain with particular abundance in the hippocampus and cerebral cortex and enters the circulation through reabsorption of cerebrospinal fluid. Thus, peripheral and central BDNF levels are closely related. 31 Findings of reduced BDNF serum concentrations in patients with depression have consistently been replicated. Clinical studies also provided clear evidence that serum BDNF can serve as a marker of antidepressant therapeutic efficacy. [12] [13] [14] 32 A study of a large community sample of middle-aged and older people has indicated that BDNF serum levels significantly decline in women with increasing age, while levels remain stable in men. A gender bias with reduction in BDNF levels in female depressed patients has also been recorded. 33, 34 In patients with hepatitis C, depressive symptoms caused by interferon-α treatment are closely related to decreased BDNF levels. 15 Our data showed that serum BDNF levels in cirrhotic patients were significantly higher than those in healthy controls. No gender or age differences in BDNF level were observed in cirrhotic patients. However, patients classified as CP class A showed higher BDNF levels than those classified as CP class B or C. Moreover, we showed that there was no significant correlation between serum BDNF levels and depression in patients with cirrhosis. This result is unexpected as BDNF has been considered a valid marker of depression. To date, few studies have evaluated the serum levels of BDNF in patients with cirrhosis. Yang et al. reported a value of 1519 (92-3220) pg/mL, which is much higher than the value found in the present study. 35 The values of serum BDNF concentrations, in published reports, in patients with hepatitis B or C vary considerably. 36, 37 These large differences may be attributable to the differences in the commercial BDNF detection kits. Interestingly, available evidence indicated that there were no significant differences in the BDNF levels between depressed and non-depressed chronic hepatitis C patients. 36 Hepatocellular carcinoma cells were reported to be an important source producing BDNF. Compared with liver donors, a significantly higher level of serum BDNF was detected in HCC patients. After resection of HCC, BDNF levels dropped considerably. 35 Hepatic stellate cells were reported to express neurotrophin receptors and produce several neurotrophins, including BDNF, in the liver. 38 Hepatic stellate cells are constantly activated during chronic hepatic injury and play an essential role in the pathogenesis of liver fibrosis. Therefore, we speculate that, in cirrhotic patients, BDNF not only acts as a neurotrophic marker but also as an important molecule associated with the severity of inflammation and fibrosis.
In summary, our data have provided evidence that female gender and GI symptoms are closely associated with depression and anxiety in patients with cirrhosis. No significant association was detected between BDNF level and psychological distress in cirrhosis. We consider that successful treatment of GI symptoms by drugs has the potential to alleviate psychological dysfunction in cirrhosis. This perspective remains to be further studied.
